SCHEMBL19208537

SCHEMBL19208537

NC(=O)c1ncnc2c1ccn2CC(=O)O

nearest known ligand 0.42

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 2/20 0.42
EGLN1 Q9GZT9 1/20 0.39
KMT2A Q03164 1/20 0.36
ABL1 P00519 1/20 0.35
BCR P11274 1/20 0.35
EGFR P00533 2/20 0.34
PTGS2 P35354 1/20 0.33
PARP1 P09874 1/20 0.33
CFD P00746 1/20 0.33
ITGB3 P05106 1/20 0.33
ITGA2B P08514 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3257655 0.82 CFD (0.45) NOTUMEGFRCFD
SCHEMBL19208090 0.80 HDAC6 (0.38) NOTUMABL1BCR
SCHEMBL4008337 0.79 NOTUM (0.47) NOTUMKMT2APTGS2
SCHEMBL28051798 0.75 NOTUM (0.51) NOTUMKMT2AABL1BCR
SCHEMBL23885229 0.73 PARP1 (0.40) NOTUMKMT2APTGS2PARP1
SCHEMBL30052421 0.73 PARP1 (0.40) NOTUMKMT2APTGS2PARP1
SCHEMBL15646004 0.71 ITGB3 (0.38) NOTUMEGLN1KMT2APARP1ITGB3
SCHEMBL21003465 0.71 LMNA (0.36) NOTUMKMT2A
SCHEMBL13146366 0.70 GRIN2B (0.39) NOTUMKMT2APTGS2
SCHEMBL6219117 0.70 ENPP3 (0.49) NOTUMKMT2APTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12485109-B2 Pyrrolo 12.3-dipyrimidine compounds and analogues thereof BIOCRYST PHARMACEUTICALS, INC. (US) 2025-12-02 US disclosed
EP-3925956-B1 1H-INDAZOLE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS FACTOR D INHIBITORS FOR TREATING DISEASES CHARACTERIZED BY ABERRANT COMPLEMENT SYSTEM ACTIVITY, SUCH AS E.G. IMMUNOLOGICAL DISORDERS BIOCRYST PHARM INC (US) 2024-04-10 EP disclosed
US-20230218578-A1 BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF WILMINGTON TRUST, NATIONAL ASSOCIATION 2023-07-13 US disclosed
US-20230218578-A1 BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF WILMINGTON TRUST, NATIONAL ASSOCIATION 2023-07-13 US disclosed
US-20230218578-A1 BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF WILMINGTON TRUST, NATIONAL ASSOCIATION 2023-07-13 US disclosed
US-11559515-B2 Indole compounds and analogues thereof BIOCRYST PHARMACEUTICALS, INC. (US) 2023-01-24 US disclosed
US-11559515-B2 Indole compounds and analogues thereof BIOCRYST PHARMACEUTICALS, INC. (US) 2023-01-24 US disclosed
CN-115490751-A Factor D inhibitors 拜奥克里斯特制药公司 2022-12-20 CN disclosed
CN-109121414-B Benzopyrazole compounds and analogs thereof 拜奥克里斯特制药公司 2022-07-05 CN disclosed
EP-3411411-B3 1H-INDAZOLE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS FACTOR D INHIBITORS FOR TREATING DISEASES CHARACTERIZED BY ABERRANT COMPLEMENT SYSTEM ACTIVITY, SUCH AS E.G. IMMUNOLOGICAL DISORDERS BIOCRYST PHARM INC (US) 2022-01-26 EP disclosed
EP-3411411-B1 1H-INDAZOLE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS FACTOR D INHIBITORS FOR TREATING DISEASES CHARACTERIZED BY ABERRANT COMPLEMENT SYSTEM ACTIVITY, SUCH AS E.G. IMMUNOLOGICAL DISORDERS BIOCRYST PHARM INC (US) 2021-05-19 EP disclosed
EP-3411411-B1 1H-INDAZOLE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS FACTOR D INHIBITORS FOR TREATING DISEASES CHARACTERIZED BY ABERRANT COMPLEMENT SYSTEM ACTIVITY, SUCH AS E.G. IMMUNOLOGICAL DISORDERS BIOCRYST PHARM INC (US) 2021-05-19 EP disclosed
US-10849883-B2 Benzopyrazole compounds and analogues thereof BIOCRYST PHARMACEUTICALS, INC. (US) 2020-12-01 US disclosed
US-10849883-B2 Benzopyrazole compounds and analogues thereof BIOCRYST PHARMACEUTICALS, INC. (US) 2020-12-01 US disclosed
US-20190142802-A1 BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF BIOCRYST PHARMACEUTICALS, INC. (US) 2019-05-16 US disclosed
US-20190142802-A1 BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF BIOCRYST PHARMACEUTICALS, INC. (US) 2019-05-16 US disclosed
CN-109121414-A Benzopyrazole compounds and analogs thereof 拜奥克里斯特制药公司 2019-01-01 CN disclosed
EP-3411411-A1 BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF Biocryst Pharmaceuticals, Inc. (US) 2018-12-12 EP disclosed
WO-2017136395-A1 BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF BIOCRYST PHARMACEUTICALS, INC. (US) 2017-08-10 WO disclosed
WO-2017136395-A1 BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF BIOCRYST PHARMACEUTICALS, INC. (US) 2017-08-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12485109-B2 Pyrrolo 12.3-dipyrimidine compounds and analogues thereof C5, DPYD, C9 NOTUM 3454/4885EGLN1 1812/4885KMT2A 4273/4885
US-20230218578-A1 BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF C9, C5, C1QBP NOTUM 1897/4885EGLN1 720/4885KMT2A 4751/4885
US-11559515-B2 Indole compounds and analogues thereof C5, IDO1, IDO2 NOTUM 1493/4885EGLN1 1583/4885KMT2A 4350/4885
US-10849883-B2 Benzopyrazole compounds and analogues thereof C9, C5, C1QBP NOTUM 1897/4885EGLN1 720/4885KMT2A 4751/4885
US-20190142802-A1 BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF C9, C5, C1QBP NOTUM 1897/4885EGLN1 720/4885KMT2A 4751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.